

2014

LRH1 as a Driving Factor for Cancer Development

Alissa M. Margraf


alissa_margraf@my.uri.edu

Creative Commons License



This work is licensed under a [Creative Commons Attribution-Noncommercial-Share Alike 3.0 License](https://creativecommons.org/licenses/by-nc-sa/3.0/).

Follow this and additional works at: <http://digitalcommons.uri.edu/srhonorsprog>

 Part of the [Digestive System Diseases Commons](#), [Medical Molecular Biology Commons](#), [Medical Pharmacology Commons](#), and the [Other Pharmacy and Pharmaceutical Sciences Commons](#)

Recommended Citation

Margraf, Alissa M., "LRH1 as a Driving Factor for Cancer Development" (2014). *Senior Honors Projects*. Paper 354.
<http://digitalcommons.uri.edu/srhonorsprog/354><http://digitalcommons.uri.edu/srhonorsprog/354>

This Article is brought to you for free and open access by the Honors Program at the University of Rhode Island at DigitalCommons@URI. It has been accepted for inclusion in Senior Honors Projects by an authorized administrator of DigitalCommons@URI. For more information, please contact digitalcommons@etal.uri.edu.

LRH-1 as a driving factor for cancer development

Department of Biomedical and Pharmaceutical Sciences, College of Pharmacy,

The University of Rhode Island

Alissa Margraf, Qi Tang, Qiushi Lin, Xiaoqun Dong

INTRODUCTION

Cancer is a major public health problem worldwide, with colon cancer ranking as the third most common cause of cancer mortality in the United States. There are an estimated 96,830 new cases and 50,310 deaths in 2014 due to colon cancer^[1](Figure1). However, the molecular mechanism of colon tumorigenesis is poorly understood and the prognosis is very bad due to multiple drug resistance. Therefore, there is urgent need to identify a novel therapeutic target. Recently, LRH1, an orphan nuclear receptor, has been identified as a key regulator for intestinal function with implications for common intestinal diseases including colorectal cancer^[2]. We hypothesize that LRH1 may be a central signaling molecule during the progression of colon cancer. To investigate this, we used the lentiviral expression system to establish stable cell lines with over-expressed LRH1 and examined that LRH1 can promote cell proliferation with MTT analysis. We will also detect the LRH1 downstream proteins' expression level by Western blot analysis.

METHODS AND MATERIALS

LRH-1 overexpressed stable cell lines Western Blot Analysis

Stable liver and pancreatic cancer cells with constitutive expression of LRH-1 were established by using the Lentiviral Expression system (GeneCopoeia). Sk-Hep-1, AsPC-1 and Capan-1 cells were infected with lentiviral particles. Twenty-four hours after infection, cells were incubated with corresponding media for 24 h, then treated with 0.8 μ g/mL (for Sk-Hep-1), 8 μ g/mL (for Capan-1) and 3 μ g/mL (for AsPC-1) puromycin overtime to eliminate uninfected cells and thus yield mass populations of puromycin-resistant cells expressing the LRH-1. The LRH-1 protein level in stable pancreatic cancer cell lines was confirmed by Western blot.

Cell lysates were treated with ConA-sepharose beads overnight followed by centrifugation to remove cadherin-bound β -catenin. Total Cell lysates and non-membrane bound cell lysates were separated by SDS PAGE and transferred to nitrocellulose membranes. Western blot analysis was performed using primary antibodies against LRH1 (Abcam, ab125034), c-Myc (Cell signaling Technology, #5605), cyclin D1 (Santa Cruz, sc-8396), cyclin E1 (Santa Cruz, sc-247), β -catenin (Cell signaling Technology, #9562), calpain1 (Santa Cruz, sc-7531), estrogen receptor alpha (ER α) (Santa Cruz, sc-7207), PCNA (Santa Cruz, sc-7907). Protein bands were visualized by IRDye® 680RD Infrared Dye and IRDye® 800CW Infrared Dye and exposed on Odyssey image system (LI-COR).

MTT Assay

Liver and pancreatic cancer cells (vectors vs. LRH1 overexpressing Sk-Hep-1, Capan-1 and AsPC-1) (1.7×10^4 cells per well) were seeded in 24 well plates and cultured for 4 days. Cells were incubated with MTT solution (Sigma-Aldrich) in medium (10% v/v) at 37 ° C for 3 h. Then 200 μ l DMSO was added. Plates were analyzed daily using a plate reader at a wavelength of 570 and 690 nm, respectively. The background absorbance of multi-well plates measured at 690 nm was subtracted from the measurement at 570 nm.

RESULTS

1. Establishment of colon cancer cell line with constitutive LRH-1 overexpression

We did transfection on 3 colon cancer cell lines (CaCo-2, LS-180 and SK-CO-1) with LRH-1 plasmid, and the results showed no or very weak LRH-1 protein expression.

2. LRH-1 upregulates downstream target proteins PCNA (in liver cancer), cyclin D1/E1, ER α and Calpain1 (in pancreatic cancer) [3,4]

We examined the potential mechanisms of LRH-1 involvement in liver and pancreatic cancer by measuring its downstream target genes. Western blot analysis revealed that PCNA, cyclin D1 and cyclin E1 (full-length [FL] and truncated T1/T2 isoforms) were upregulated by LRH-1 in stable PC cells, Cyclin E is converted to T1/T2 by calpain1 through post-translational processing. LRH1-mediated cyclin E T1/T2 overexpression was attributed to upregulation of ER α -Calpain1 signaling (Fig. 2).

3. LRH-1 promotes liver and pancreatic cancer cell proliferation

LRH-1 overexpression resulted in a significant increase in liver and pancreatic cancer cell proliferation compared with the control (Fig. 3).

4. Tumorigenicity of LRH-1 *in vivo*

In vitro observations suggest that LRH-1 expression is important for pancreatic cancer cell proliferation. Therefore, we explored its oncogenic role *in vivo* using a murine subcutaneous (s.c.) model (Fig. 5). We measured the resulting tumor growth in the immune deficient mice after injection of parental and LRH-1-transfected pancreatic cancer cells. Following introduction and expression of LRH-1, Capan-1 cells generated significantly enhanced subcutaneous tumor growth characterized by a significantly increased tumor weight compared to vectors.

FIGURES

	ESTIMATED NEW CASES				ESTIMATED DEATHS			
	BOTH SEXES	MALE	FEMALE	BOTH SEXES	MALE	FEMALE		
All sites	1,685,540	855,220	810,320	585,720	316,010	275,710		
Oral cavity & pharynx	42,440	30,220	12,220	8,390	5,730	2,660		
Tongue	13,590	9,720	3,870	2,150	1,460	700		
Mouth	11,920	7,150	4,770	2,070	1,130	940		
Pharynx	14,410	11,550	2,860	2,540	1,900	640		
Other oral cavity	2,520	1,800	720	1,630	1,250	380		
Digestive system	289,810	162,720	126,890	147,280	84,970	62,290		
Esophagus	18,170	14,660	3,510	15,450	12,450	3,000		
Stomach	22,220	13,720	8,490	10,990	6,720	4,270		
Small intestine	9,160	4,860	4,290	1,210	640	570		
Colon ¹	96,830	48,450	48,380	50,310	26,270	24,040		
Rectum	40,000	23,360	16,620	900	370	530		
Anus, anal canal, & anorectum	7,210	2,950	4,260	900	370	530		
Liver & intrahepatic bile duct	28,190	24,800	3,390	20,000	16,870	3,130		
Gallbladder & other biliary	10,650	4,960	5,690	3,820	1,610	2,210		
Pancreas	48,420	23,520	24,900	39,590	20,170	19,420		
Other digestive organs	5,760	1,860	3,900	2,130	870	1,260		
Respiratory system	242,650	120,000	112,550	163,660	90,280	73,380		
Larynx	12,820	10,020	2,800	3,810	2,870	940		
Lung & bronchus	224,210	116,000	108,210	159,280	86,930	72,350		
Other respiratory organs	5,710	4,000	1,710	790	480	310		
Bones & joints	3,020	1,680	1,340	1,460	830	630		
Soft tissue (including heart)	12,020	6,590	5,470	4,740	2,500	2,190		
Skin (excluding basal & squamous)	81,220	46,830	34,390	12,880	8,840	4,140		
Melanoma-skin	76,100	43,890	32,210	9,710	6,470	3,240		
Other non-melanoma skin	5,120	2,740	2,380	3,270	2,370	900		
Breast	235,930	2,360	232,670	48,430	430	48,000		
Genital system	338,450	243,460	94,990	58,970	30,180	28,790		
Uterine cervix	12,360	12,360	0,000	0,000	0,000	0,000		
Uterine corpus	52,630	52,630	0,000	8,590	8,590	0,000		
Ovary	21,960	21,960	0,000	14,270	14,270	0,000		
Vulva	4,850	4,850	0,000	1,030	1,030	0,000		

Fig.1. Estimated new cancer cases and deaths by sex, United States, 2014




Fig.2. LRH-1 upregulated downstream target genes in liver cancer and pancreatic cancer cells.




Fig.3. Growth curves of liver and pancreatic cancer cells with LRH-1 overexpression. Accelerated cell growth was observed in LRH-1 overexpressed Sk-Hep-1 (Liver cancer), Capan-1 and AsPC-1 (Pancreatic cancer) cells than in controls (Student t test, 2-tailed, *p<0.05).




Fig.4. LRH-1 promote cell proliferation by inducing Cyclin D1 and E1 through β -catenin/Tcf-4 signaling pathway.





Fig.5. LRH-1 promoted pancreatic tumor growth in nude mice. The subcutaneous tumor model was established by inoculation of Capan-1 cells transfected with LRH-1 and Vector control. Compared to vectors, LRH-1 overexpression cells produced larger size tumors (paired t test, 2 tailed, **p<0.01).

FUTURE WORK

- Establish other stable pancreatic and colon cancer cell lines overexpressing LRH-1 using lentiviral expression system.
- Confirm the expression of LRH-1 by Western blot and RT-PCR.
- Examine the expression levels of cancer stem cell markers: CD24 / CD44 / ESA / c-MET / ALDH
- Determine if LRH-1 overexpression enhances migration, invasion and sphere formation of pancreatic and colon cancer cells.

REFERENCES

- [1] Rebecca Siegel, Jiemin Ma, Zhaohui Zou, et al. Cancer Statistics, 2014. CA Cancer J Clin. 2014; 64:9-29.
- [2] K. Schoonjans, L. Dubuquoy, J. Mebis, E. Fayard, O. Wendling, C. Haby, K. Geboes, J. Auwerx, Liver receptor homolog 1 contributes to intestinal tumor formation through effects on cell cycle and inflammation, Proc. Nat. Acad. Sci. USA 2005;102:2058–2062.
- [3] Lin Q, Aihara A, Chung W, Li Y, Huang Z, Chen X, Weng S, Carlson R, Shaikh Z, Wands J, Dong X. LRH1 promotes pancreatic cancer metastasis. Cancer Lett. in press
- [4] Lin Q, Aihara A, Chung W, Li Y, Huang Z, Chen X, Weng S, Carlson R, Wands J, Dong X. LRH1 as a driving factor in pancreatic cancer growth. Cancer Lett. 2014;345:85-90. Epub 2013 Dec 11.

ACKNOWLEDGEMENT

Professor Jack R. Wands
Liver Research Center, Division of Gastroenterology, Warren Alpert Medical School of Brown University